Invivyd Completes Enrollment Phase 3 LIBERTY Trial Of Covid-19 Monoclonal Antibody VYD2311 With An mRNA Covid-19 Vaccine, Topline Data Expected in Q3 2026

Loading news article.

Invivyd Completes Enrollment Phase 3 LIBERTY Trial Of Covid-19 Monoclonal Antibody VYD2311 With An mRNA Covid-19 Vaccine, Topline Data Expected in Q3 2026 | WAPE

Invivyd Completes Enrollment Phase 3 LIBERTY Trial Of Covid-19 Monoclonal Antibody VYD2311 With An mRNA Covid-19 Vaccine, Topline Data Expected in Q3 2026

Article summary

Related companies

Comments —